



(51) International Patent Classification:

C12N 5/10 (2006.01) C12N 15/85 (2006.01)
C12N 15/63 (2006.01)

(21) International Application Number:

PCT/US2022/023673

(22) International Filing Date:

06 April 2022 (06.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English


(30) Priority Data:

63/171,227 06 April 2021 (06.04.2021) US

(71) Applicant: **SENTI BIOSCIENCES, INC.** [US/US]; 2 Corporate Drive, First Floor, South San Francisco, California 94080 (US).(72) Inventors: **HUNG, Michelle Elizabeth**; c/o Senti Biosciences, Inc., 2 Corporate Drive, First Floor, South San Francisco, California 94080 (US). **COTTMAN, Rebecca Tayler**; c/o Senti Biosciences, Inc., 2 Corporate Drive, First Floor, South San Francisco, California 94080 (US). **GORDLEY, Russell Morrison**; c/o Senti Biosciences, Inc., 2 Corporate Drive, First Floor, South San Francisco, California 94080 (US). **LEE, Gary**; c/o Senti Biosciences,Inc., 2 Corporate Drive, First Floor, South San Francisco, California 94080 (US). **LU, Timothy Kuan-Ta**; c/o Senti Biosciences, Inc., 2 Corporate Drive, First Floor, South San Francisco, California 94080 (US). **KANNAN, Srinivasaraghavan**; c/o Senti Biosciences, Inc., 2 Corporate Drive, First Floor, South San Francisco, California 94080 (US). **VERMA, Chandra Shekhar**; c/o Senti Biosciences, Inc., 2 Corporate Drive, First Floor, South San Francisco, California 94080 (US).(74) Agent: **KABLER, Kevin** et al.; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept./7th FL, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: ERT2 MUTANTS AND USES THEREOF



Mutations

FIG. 1A

(57) Abstract: Provided herein are mutants of estrogen receptor alpha ligand binding domain (ER-LBD), and chimeric proteins including such mutant ER-LBD. Also provided are methods of modulating transcription and modulating localization of such chimeric proteins.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*